AMG.DE लाइव सिग्नल्स | Getagraph.com के साथ लाभ को अधिकतम करें

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 21:05):

Stats
आज की मात्रा	136.00
औसत मात्रा	594.00
बाजार मूल्य	135.19B
EPS	€0 ( 2024-04-24 )
अगली कमाई की तारीख	( €0 ) 2024-05-01
Last Dividend	€2.13 ( 2023-08-17 )
Next Dividend	€0 ( N/A )
P/E	21.63
ATR14	€0.763 (0.30%)

Amgen Inc सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध

10 सबसे अधिक नकारात्मक सहसंबंध

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

Amgen Inc वित्तीय

Annual	2023
राजस्व:	€28.19B
सकल लाभ:	€19.74B (70.02 %)
EPS:	€12.56

FY	2023
राजस्व:	€28.19B
सकल लाभ:	€19.74B (70.02 %)
EPS:	€12.56

FY	2022
राजस्व:	€26.32B
सकल लाभ:	€19.92B (75.66 %)
EPS:	€12.18

FY	2021
राजस्व:	€25.98B
सकल लाभ:	€19.53B (75.16 %)
EPS:	€9.74

Financial Reports:

No articles found.

Amgen Inc Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
€1.940 (N/A)	€1.940 (N/A)	€2.13 (N/A)	€2.13 (N/A)	€2.13 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)

Amgen Inc Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 4.55 - Stable (8.94%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	€0.280	2011-08-16
Last Dividend	€2.13	2023-08-17
Next Dividend	€0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	49	--
Total Paid Out	€56.75	--
Avg. Dividend % Per Year	0.00%	--
Score	4.22	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	4.55
Div. Directional Score	7.43	--

Next Divdend (Est)
(2024-07-01)

€2.17 Estimate 22.19 %

Dividend Stability

0.59 Average

Dividend Score

4.22

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for XETRA

Symbol	Title	Last dividend	Frequency	Yearly Dividend
SAP.DE	Ex Dividend Knight	2023-05-12	Annually	0.00%
CBHD.DE	Ex Dividend Knight	2023-05-15	Semi-Annually	0.00%
KHNZ.DE	Ex Dividend Knight	2023-08-31	Quarterly	0.00%
TNE5.DE	Ex Dividend Junior	2023-12-12	Semi-Annually	0.00%
DR0.DE	Ex Dividend Junior	2023-06-30	Sporadic	0.00%
MUB.DE	Ex Dividend Junior	2023-08-11	Annually	0.00%
7BP.F	Ex Dividend Knight	2023-09-06	Annually	0.00%
WIB.DE	Ex Dividend Knight	2023-05-09	Annually	0.00%
FME.DE	Ex Dividend Knight	2023-05-17	Annually	0.00%
PBB.DE	Ex Dividend Junior	2023-05-26	Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.238	1.500	5.23	7.85	[0 - 0.5]
returnOnAssetsTTM	0.0691	1.200	7.70	9.23	[0 - 0.3]
returnOnEquityTTM	1.033	1.500	10.00	10.00	[0.1 - 1]
payoutRatioTTM	0.678	-1.000	3.22	-3.22	[0 - 1]
currentRatioTTM	1.649	0.800	6.75	5.40	[1 - 3]
quickRatioTTM	1.027	0.800	8.67	6.93	[0.8 - 2.5]
cashRatioTTM	0.595	1.500	7.81	10.00	[0.2 - 2]
debtRatioTTM	0.665	-1.500	10.00	-10.00	[0 - 0.6]
interestCoverageTTM	3.15	1.000	9.94	9.94	[3 - 30]
operatingCashFlowPerShareTTM	15.83	2.00	4.72	9.44	[0 - 30]
freeCashFlowPerShareTTM	13.76	2.00	3.12	6.24	[0 - 20]
debtEquityRatioTTM	10.37	-1.500	10.00	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.700	1.000	1.663	1.663	[0.2 - 0.8]
operatingProfitMarginTTM	0.321	1.000	5.57	5.57	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.131	1.000	-0.383	-0.383	[0.2 - 2]
assetTurnoverTTM	0.290	0.800	-1.399	-1.119	[0.5 - 2]
Total Score				10.30

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	21.50	1.000	7.93	0	[1 - 100]
returnOnEquityTTM	1.033	2.50	3.34	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	13.76	2.00	5.41	6.24	[0 - 30]
dividendYielPercentageTTM	3.20	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	15.83	2.00	4.72	9.44	[0 - 30]
payoutRatioTTM	0.678	1.500	3.22	-3.22	[0 - 1]
pegRatioTTM	-5.58	1.500	-10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.300	1.000	4.99	0	[0.1 - 0.5]
Total Score				4.55

Amgen Inc

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

के लिए वास्तविक समय के अद्यतन Amgen Inc [AMG.DE]

Upcoming Earnings Alert

Amgen Inc Dividend Information - Ex Dividend Knight

Dividend Commentary

Top 10 dividend Companies for XETRA

Dividend Sustainability Score (DSS)

Dividend Growth Score (DGS)